



We report a case of a cerebral venous thrombosis
(CVT) in a chronic kidney disease patient with three
CVT predisposing conditions. A 53 year-old woman on
chronic peritoneal dialysis presented to the emergency
department with acute headache and vertigo. The neu-
rological examination and head CT scan performed at
the emergency department were normal but, three days
later, a lateral gait deviation and a horizontal nystag-
mus were identified. A brain MRI and MRI-venogram
confirmed a left lateral sinus thrombosis. Hormonal
replacement therapy (HRT), a positive lupus anticoag-
ulant and a homozygous mutation on the methylenete-
trahydrofolate reductase gene, with hyperhomocys-
teinaemia, were the three well-known prothrombotic
conditions identified in this patient. HRT was discon-
tinued, the patient started anticoagulation with war-
farin and folic acid supplementation and was dis-
charged, 10 days after admission, complaining of a mild
vertigo. After six months of therapy the patient had
vertigo improvement and maintained a positive lupus
anticoagulant. The head MRI and MRI-venography
showed a thrombus reduction. 
The rather unexpected finding of three CVT pre-
disposing conditions in this patient stresses the need
of a broad diagnostic approach in CVT. The diagno-
sis of antiphospholipid syndrome implies life-long
anticoagulation. 
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 CASE PRESENTATION
A 53 year-old female patient presented to the
emergency department in March 2004 with an intense,
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constant, occipital headache aggravated with Valsal-
va manoeuvers and associated with vertigo, nausea,
vomiting and gait disturbance. This severe headache
had been preceded a day earlier by a milder, unilat-
eral, pulsatile headache, similar to previous migraine
crisis. The patient had a prior history of hypertension,
migraine, autosomal dominant polycystic kidney dis-
ease (APKD), with a negative family history for cere-
bral aneurysms, and she had been on automated peri-
toneal dialysis (APD) since April 2003. She denied any
previous venous or arterial thrombosis or any obstet-
ric complications but was on hormonal replacement
therapy with transdermal oestrogen. 
Physical examination revealed an alert and orien-
tated patient, with normal vital signs. Neurological
and otorhinolaryngological examinations were nor-
mal. Laboratory tests were normal except for a pro-
longed partial thromboplastin time (29/27 seconds)
and the expected elevation of serum creatinine and
urea levels. Head CT Scan was normal and the patient
was admitted to the Nephrology department. 
Three days later, the patient was still symptomatic
and a second neurological evaluation revealed a lat-
eral gait deviation and horizontal nystagmus, with a
right fast component. She then underwent a brain MRI
and venogram-MRI (Fig. 1) that revealed a left later-
al sinus thrombosis and excluded cerebral aneurysms
or vascular malformations. Thrombophilia evaluation
demonstrated a positive lupus anticoagulant and
hyperhomocysteinaemia (22 μmol/L) associated with
a homozygous VAL/VAL mutation on the 5,10-methylene-
-tetrahydrofolate-redutase (MTHFR) gene (Fig. 2) and
low seric folate levels. Activated protein C resistance,
factor V Leiden, G/A 20210 prothrombin gene muta-
tion, antithrombin III, protein C and protein S deficien-
cies and other antiphospholipid antibodies were
excluded. Systemic lupus erythematosus serology was
negative.
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Figure 1
MRI and MRI venogram. Left lateral sinus thrombus (arrows).
Figure 2
Polymerase Chain Reaction (PCR) analysis of MTHFR 677C/T allele poly-
morphism (or VAL-VAL mutation). Amplification with PCR followed by diges-
tion with a restriction enzyme Hinf I. After digestion the PCR products were
subjected to electrophoresis in acrilamide gel coloured with silver stain-
ing: Hinf I digested PCR fragments from the 677C/T mutation (M) and from
the normal alelle (N). Lane1 – Molecular weight marker; Lane 2 – 677CT
homozygous (arrow); Lane 3 – wild type (2 normal alelles); Lane 4 – 677CT
heterozygous and Lane 5 – PCR (undigested control fragment).
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The patient initiated therapy with enoxaparin, war-
farin and acid folic supplementation. Hormonal
replacement therapy was discontinued. There was a
progressive clinical improvement and the patient was
discharged ten days later with mild vertigo and receiv-
ing warfarin (INR target of 2-3) and oral folic acid.
After 6 months, the patient had vertigo improvement
and the MRI and venography-MRI (Fig. 3) demonstrat-
ed a thrombus reduction and permeabilisation of the
left lateral sinus.
 DISCUSSION
CVT is a rare condition1 that results from a com-
plete or partial occlusion of a cerebral vein or cere-
bral dural sinus by a thrombus. Venous obstruction
may lead to cerebral parenchyma infarction, which
was not the case in our patient. The superior sagi-
tal sinus (62%), left lateral sinus (44.7%) and right
lateral sinus (41.2%) are the most frequently occlud-
ed venous sinus and in 50% of cases it is possible
to demonstrate the involvement of multiple sinus2. 
Cerebral venous thrombosis has an estimated annu-
al incidence3 of three to four cases in 106 individu-
als. In the International Study on Cerebral Vein Throm-
bosis (ISCVT), the 624 patients had a mean age of
39 years old and 75% were female.  Other studies4
confirmed the higher prevalence of CVT in women,
particularly those aged 20 to 35 years old. 
In the ISCVT, 87.5% of patients had CVT risk factors
and in 43.6% they were multiple. Thrombophilia (34.1%),
oral contraceptives (54.3%), pregnancy-puerperium
(20.1%), neoplasia (7.4%) and infections (12.3%) (e.g.
ear-nose-throat, central nervous system) were within the
most prevalent prothrombotic conditions identified. Our
patient had at least three recognised predisposing con-
ditions to CVT (lupus anticoagulant, hyperhomocystei-
naemia and hormonal replacement therapy). 
CVT belongs to the spectrum of neurological man-
ifestations of antiphospholipid syndrome5 and its
association with lupus anticoagulant is well des-
cribed6-9, although it is seldom the first manifesta-
tion of antiphospholipid syndrome in a middle-aged
patient. Martinelli et al 10 have demonstrated that
hyperhomocysteinaemia is associated with an
increased risk for CVT. Hyperhomocysteinaemia is
prevalent in chronic kidney disease patients, which
is probably related to a reduction in the renal clear-
ance of seric homocysteine11. Some forms of MTH-
FR gene mutation11, namely the homozygous MTH-
FR 677C/T mutation diagnosed in this case, have a
greater impact in homocysteine levels elevation in
the context of low folate levels, and supplementa-
tion with folic acid is a logical intervention in patients
with these findings. 
Homozygous C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene 
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Figure 3
MRI venogram at 6 months. Partial recanalisation of left lateral sinus (arrow).
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Various drugs have been associated with CVT,
namely oral contraceptives2,12-14 and hormonal
replacement therapy15. In the ISCVT, 54.3% of the 381
female patients aged below 50 were on oral contra-
ceptives. Oral hormonal replacement therapy (HRT)
is associated with a state of activated C protein resist-
ance, not related with factor V Leiden, which may pre-
dispose to venous thrombosis15,16. Although this has
not been demonstrated in transdermic HRT, it seemed
adequate to discontinue the HRT in this patient.
Clinical manifestations of CVT are extremely vari-
able. CVT may have an acute (37.2%), sub-acute
(55.5%) or a chronic (7.2%) presentation and head-
ache (88.8%), with convulsion (39.4%) and paresis
(37.2%) the most frequent clinical manifestations
identified2. Our patient had a clinical presentation
of intracranial hypertension associated with vertigo.
In 23% of ISCVT cases the clinical presentation is
that of an intracranial hypertension. Vertigo, howev-
er, is a rare symptom of CVT and in our patient, it
was probably related to vestibular dysfunction due
to venous flux obstruction of the VIII cranial nerve.
CVT is diagnosed by identifying the thrombus and
occlusion of the sinus by MRI, venography-MRI or cere-
bral angiography. Head CT scan is usually non-diag-
nostic and associated with a significant percentage
of false-negatives18, as was the case in our patient. 
Treatment of CVT involves anticoagulant therapy,
symptomatic treatment, with anticonvulsivants and
analgesics, measures to reduce intracranial hyperten-
sion and aetiological treatment (e.g. infection). Non-
fractionated intravenous heparin or subcutaneous
low-molecular weight heparins can be used initially
followed by oral anticoagulation. Local thrombolyt-
ic therapy is reserved for patients with clinical dete-
rioration despite conservative therapy19. Our patient
was treated with enoxaparin followed by warfarin with
clinical improvement. We adjusted warfarin doses to
an INR target of 2 to 3 based on recent reports20,21
which showed that this is a safe approach.
The diagnosis of antiphospholipid syndrome
implied the recommendation of life-long therapy with
warfarin and regular screening with brain MRI and
veno-MRI for assessment of the venous thrombus evo-
lution and development of cerebral aneurysms (APKD).
Discontinuation of HRT and supplementation with
folate were other therapeutic measures in this case. 
CVT has traditionally been associated with a bad
prognosis, although recent studies have changed this
perspective. In ISCVT, nearly 60% of the patients were
completely asymptomatic and the mortality rate was
8.3%, in a median follow-up period of 16 months. 
This CVT clinical case presented with several sin-
gularities worth stressing. First, the need to thorough-
ly evaluate a patient with acute headache and to
exclude CVT even in the presence of a normal CT
scan. Second, the finding of three predisposing fac-
tors to CVT in this patient, reflecting the need for a
systematic and broad diagnostic approach. Evalua-
tion of thrombophilia had a significant impact and
implied the recommendation of permanent antico-
agulation and supplementation with oral folate. Final-
ly, the use of the minimum efficacious dose of oral
anticoagulant is important to lessen the increased
risk of haemorrhagic complications (e.g. haemocyst)
in this patient.
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